Skip to main content
. Author manuscript; available in PMC: 2014 Oct 3.
Published in final edited form as: JAMA. 2013 Oct 2;310(13):1353–1368. doi: 10.1001/jama.2013.278040

Figure 2.

Figure 2

Number of events (annualized %), difference in absolute risks per 10,000 person–years, and hazard ratios (95%CI) for various health outcomes in the overall study population in the WHI Hormone Therapy Trials (intervention phase). The total cardiovascular disease outcome includes MI, CHD death, angina, heart failure, CABG/PCI, stroke, carotid artery disease, peripheral vascular disease, venous thromboembolism, and cardiovascular death.